CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. has announced the appointment of three new members to its leadership team. The additions come as the firm prepares for the market launch of resmetirom, a first-of-its-kind treatment for non-alcoholic steatohepatitis (NASH) with significant fibrosis.
Mark Barrett joins Madrigal as Chief Business Officer, bringing over 25 years of biopharmaceutical leadership and industry experience. Barrett’s extensive experience includes successful partnerships and acquisitions, building commercial portfolios, and developing R&D pipelines across various therapeutic areas. His most recent role was co-founder, Director, and CEO of Lassen Therapeutics, a biotech company specializing in novel antibody therapeutics. Prior to that, he held leadership positions at Johnson & Johnson and Sanofi.
Clint Wallace, the newly appointed Chief Human Resources Officer, joins Madrigal from Kenvue, where he served as Senior Vice President Human Resources, Global Functions and Organizations. With a wealth of experience in HR leadership roles at companies like Sanofi, BASF Corporation, GE Healthcare, and Pratt & Whitney, Wallace’s expertise will be invaluable in shaping Madrigal’s organizational design and talent succession strategy.
Tina Ventura, the new Chief Investor Relations Officer, brings nearly 25 years of global health care investor relations and communications experience to Madrigal. Her tenure includes serving as Chief Investor Relations Officer at Horizon Therapeutics, where she led efforts to shape the company’s investment identity as a rare disease-focused biotech firm. Previous to Horizon, Ventura held various roles at Abbott, including Divisional Vice President, Investor Relations.
Bill Sibold, Chief Executive Officer of Madrigal, expressed his enthusiasm about the new appointments. “As we prepare for a first-to-market launch of resmetirom in NASH with significant fibrosis, we are also building a foundation for enduring leadership. These new leaders are not only experts in their respective areas but have experience scaling teams and organizations. They will each play a pivotal role in Madrigal’s next phase of growth.”
With these strategic appointments, Madrigal Pharmaceuticals is poised to navigate its upcoming launch and future growth with a strengthened leadership team. The combined expertise of Barrett, Wallace, and Ventura will undoubtedly contribute to the company’s ongoing mission to develop innovative therapies for cardiovascular, metabolic, and liver diseases.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.